132 related articles for article (PubMed ID: 25043693)
21. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
22. Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Sucker A; Placke JM; Zaremba A; Albrecht LJ; Kowall B; Galetzka W; Becker JC; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Schadendorf D; Ugurel S; Griewank K
Eur J Cancer; 2023 Apr; 183():1-10. PubMed ID: 36773463
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of BRAF mutations in localized cutaneous melanoma.
Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E
J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723
[TBL] [Abstract][Full Text] [Related]
24. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
27. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
28. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
[TBL] [Abstract][Full Text] [Related]
29. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
30. KIT, NRAS, and BRAF mutations in nail apparatus melanoma.
Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA
Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496
[No Abstract] [Full Text] [Related]
31. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
32. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
33. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the BRAF V600E mutation in primary cutaneous melanoma.
Inumaru JS; Gordo KI; Fraga Junior AC; Silva AM; Leal CB; Ayres FM; Wastowski IJ; Borges NF; Saddi VA
Genet Mol Res; 2014 Jan; 13(2):2840-8. PubMed ID: 24535907
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
36. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
[TBL] [Abstract][Full Text] [Related]
37. RAC1 and melanoma.
Halaban R
Clin Ther; 2015 Mar; 37(3):682-5. PubMed ID: 25465943
[TBL] [Abstract][Full Text] [Related]
38. RAC1P29S is a spontaneously activating cancer-associated GTPase.
Davis MJ; Ha BH; Holman EC; Halaban R; Schlessinger J; Boggon TJ
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):912-7. PubMed ID: 23284172
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.
Voskoboynik M; Mar V; Mailer S; Colebatch A; Fennessy A; Logan A; Hewitt C; Cebon J; Kelly J; McArthur G
Pigment Cell Melanoma Res; 2016 Mar; 29(2):222-8. PubMed ID: 26643848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]